Literature DB >> 7159273

Fibrinolysis-coagulation system in patients with cancer of the head and neck. Preliminary report.

T Kosugi, I Takagi, Y Ariga, S Okada, T Morimitsu, H Mihara.   

Abstract

Five parameters of blood coagulation and fibrinolysis, viz., levels of fibrinogen, fibrinolytic activity of euglobulin, fibrinogen and/or fibrin-degradation products (FDP), antiplasmin activity, and antithrombin activity, were measured in patients with cancer of the head and neck, and the results were compared with those of healthy adults. The fibrinogen content in cancer was significantly increased (p less than 0.001), the fibrinolytic activity of euglobulin significantly enhanced (p less than 0.001), the antiplasmin activity significantly reduced (p less than 0.05), the antithrombin activity significantly reduced (p less than 0.001), and the FDP level slightly increased, although the difference was not significant. The importance of the coagulation and fibrinolytic system in cancer of the head and neck is discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7159273     DOI: 10.1007/bf00454212

Source DB:  PubMed          Journal:  Arch Otorhinolaryngol        ISSN: 0302-9530


  8 in total

1.  The fibrin plate method for estimating fibrinolytic activity.

Authors:  T ASTRUP; S MULLERTZ
Journal:  Arch Biochem Biophys       Date:  1952-10       Impact factor: 4.013

2.  Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251.

Authors:  P Friberger; M Knös; S Gustavsson; L Aurell; G Claeson
Journal:  Haemostasis       Date:  1978

3.  The detection of fibrinogen-fibrin degradation products by means of a new antibody-coated latex particle.

Authors:  M B Garvey; J M Black
Journal:  J Clin Pathol       Date:  1972-08       Impact factor: 3.411

4.  Unreliability of chromogenic substrates for assay of the clotting activity of thrombin.

Authors:  P J Gaffney; M Miller-Andersson; T B Kirkwood
Journal:  Haemostasis       Date:  1978

5.  Problems in the assay of thrombin using synthetic peptides as substrates.

Authors:  P J Gaffney; K Lord; M Brasher; T B Kirkwood
Journal:  Thromb Res       Date:  1977-04       Impact factor: 3.944

Review 6.  Malignancy and haemostasis.

Authors:  M B Donati; A Poggi
Journal:  Br J Haematol       Date:  1980-02       Impact factor: 6.998

7.  Standard for human thrombin.

Authors:  I Robertson; P J Gaffney; D R Bangham
Journal:  Thromb Diath Haemorrh       Date:  1975-09-30

8.  Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate.

Authors:  A C Teger-Nilsson; P Friberger; E Gyzander
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

  8 in total
  2 in total

1.  Identification of a plasminogen activator derived from nasopharyngeal carcinoma.

Authors:  T Kosugi; G W Huang; M Nakamura; S Koja; H T Nong
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

Review 2.  Platelet and Cancer-Cell Interactions Modulate Cancer-Associated Thrombosis Risk in Different Cancer Types.

Authors:  Ana-Luisa Palacios-Acedo; Mélanie Langiu; Lydie Crescence; Diane Mège; Christophe Dubois; Laurence Panicot-Dubois
Journal:  Cancers (Basel)       Date:  2022-01-30       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.